###begin article-title 0
Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease
###end article-title 0
###begin p 1
Conceived and designed the experiments: KS WR MG TI CH. Performed the experiments: KS WR. Analyzed the data: KS WR MG JE HS TI CH. Contributed reagents/materials/analysis tools: JE CH. Wrote the paper: KS WR MG JE HS CH.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 54 66 <span type="species:ncbi:9606">participants</span>
###xml 360 372 <span type="species:ncbi:9606">participants</span>
Recently, a large meta-analysis including over 28,000 participants identified nine different loci with association to serum uric acid (UA) levels. Since elevated serum UA levels potentially cause gout and are a possible risk factor for coronary artery disease (CAD) and myocardial infarction (MI), we performed two large case-control association analyses with participants from the German MI Family Study. In the first study, we assessed the association of the qualitative trait gout and ten single nucleotide polymorphisms (SNP) markers that showed association to UA serum levels. In the second study, the same genetic polymorphisms were analyzed for association with CAD.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 478 484 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 544 549 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 578 579 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 588 590 588 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 602 604 602 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 620 622 620 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 663 668 663 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDZK1</italic>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 676 683 676 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRC16A</italic>
###xml 685 692 685 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A1</italic>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A3</italic>
###xml 702 709 702 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC16A9</italic>
###xml 711 719 711 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC22A11</italic>
###xml 724 732 724 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC22A12</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
A total of 683 patients suffering from gout and 1,563 healthy controls from the German MI Family Study were genotyped. Nine SNPs were identified from a recently performed genome-wide meta-analysis on serum UA levels (rs12129861, rs780094, rs734553, rs2231142, rs742132, rs1183201, rs12356193, rs17300741 and rs505802). Additionally, the marker rs6855911 was included which has been associated with gout in our cohort in a previous study. SNPs rs734553 and rs6855911, located in SLC2A9, and SNP rs2231142, known to be a missense polymorphism in ABCG2, were associated with gout (p = 5.6*10-7, p = 1.1*10-7, and p = 1.3*10-3, respectively). Other SNPs in the genes PDZK1, GCKR, LRRC16A, SLC17A1-SLC17A3, SLC16A9, SLC22A11 and SLC22A12 failed the significance level. None of the ten markers were associated with risk to CAD in our study sample of 1,473 CAD cases and 1,241 CAD-free controls.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
SNP markers in SLC2A9 and ABCG2 genes were found to be strongly associated with the phenotype gout. However, not all SNP markers influencing serum UA levels were also directly associated with the clinical manifestation of gout in our study sample. In addition, none of these SNPs showed association with the risk to CAD in the German MI Family Study.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 62 65 62 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Campion1">[1]</xref>
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 298 301 298 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Li1">[2]</xref>
###xml 302 305 302 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 393 400 393 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A3</italic>
###xml 455 458 455 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 617 620 617 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 710 715 710 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDZK1</italic>
###xml 717 721 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 723 730 723 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRC16A</italic>
###xml 732 739 732 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC16A9</italic>
###xml 744 752 744 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC22A11</italic>
###xml 803 816 803 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2, SLC2A9</italic>
###xml 821 828 821 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A1</italic>
###xml 829 836 829 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A3</italic>
###xml 873 881 873 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC22A12</italic>
###xml 998 1001 998 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 604 616 <span type="species:ncbi:9606">participants</span>
Gout is mainly caused by elevated serum uric acid (UA) levels [1]. Several studies showed significant association between single nucleotide polymorphism (SNP) markers in SLC2A9 gene (solute carrier family 2, member 9, also known as GLUT9 gene) and serum UA levels as well as susceptibility to gout [2]-[6]. Additionally, Dehghgan et al. reported association between markers in genes ABCG2 and SLC17A3 with both, serum UA levels and gout in a large cohort [6]. Very recently, Kolz et al. conducted a meta-analysis of 14 genome-wide association (GWA) studies on serum UA levels including a total of 28,141 participants [7]. Nine loci with significant associations to serum UA levels were found, namely the genes PDZK1, GCKR, LRRC16A, SLC16A9 and SLC22A11 together with the previously reported findings in ABCG2, SLC2A9 and SLC17A1-SLC17A3, as well as the intensively studied SLC22A12 gene encoding for URAT1. Therefore, five novel loci associated with serum UA levels emerged from this meta-analysis [7]. The advantage of this GWA-based meta-analysis is its power to detect novel common variants with relatively small phenotypic effects on serum UA due to the large sample size.
###end p 9
###begin p 10
We analyzed these new and known loci for their association with the clinical phenotype gout in a case control study.
###end p 10
###begin p 11
###xml 126 129 126 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Culleton1">[8]</xref>
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Niskanen1">[10]</xref>
Elevated serum UA levels are potentially increasing the risk for coronary artery disease (CAD) and myocardial infarction (MI) [8]-[10]. We therefore tested additionally for the influence of these SNP markers on the susceptibility to CAD in our German MI Family Study.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
Ethics Statement
###end title 13
###begin p 14
###xml 89 101 <span type="species:ncbi:9606">participants</span>
The Ethics committee of the University of Regensburg approved the study protocol and all participants gave their written informed consent at the time of inclusion and again at the time of follow-up investigations. The study was in accordance with the principles of the current version of the Declaration of Helsinki.
###end p 14
###begin title 15
Case-Control Samples and Phenotyping
###end title 15
###begin p 16
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 180 183 180 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Stark1">[3]</xref>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 384 387 384 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Stark1">[3]</xref>
All individuals of this study participated in the German MI Family Study (total n = 7,575). Recruitment process, selection criteria and study details have been reported previously [3]. A total of n = 683 unrelated individuals (n = 480 males, n = 203 females) with the diagnosis of gout were selected from the German MI Family Study. Phenotyping was carried out as reported previously [3]. In brief, the phenotype gout was established using medical history readings and self-reported history of gout.
###end p 16
###begin p 17
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 276 283 276 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t001">Table 1</xref>
Controls (n = 1,563) were unrelated individuals from our German MI Family Study who neither had any indication of gout nor were they medicated with uricostatic or uricosuric agents at any time during follow-up (n = 871 males, n = 692 females). Phenotypic details are shown in Table 1.
###end p 17
###begin title 18
Characteristics of gout case and control study sample.
###end title 18
###begin p 19
Values denote means+/-standard deviations unless indicated otherwise. n. s., not significant; CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
###end p 19
###begin p 20
At inclusion to study.
###end p 20
###begin p 21
Defined as LDL-C >/=160 mg/dL or intake of lipid lowering medication.
###end p 21
###begin p 22
Defined as blood pressure >/=140/90 mmHg or ongoing antihypertensive therapy.
###end p 22
###begin p 23
Defined as history of diabetes mellitus or intake of antidiabetic medication.
###end p 23
###begin p 24
Former or current smoking habit.
###end p 24
###begin p 25
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 567 574 567 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t002">Table 2</xref>
Furthermore, a large case-control sample was established from the German MI Family Study including n = 1,473 CAD/MI unrelated cases (n = 856 males, n = 617 females) and n = 1,241 unrelated CAD/MI-free control individuals (n = 336 males, n = 905 females). MI was diagnosed according to MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) diagnostic criteria (). Severe CAD was defined as prior MI, treatment with percutaneous coronary intervention or coronary artery bypass graft. Cardiovascular risk factors and phenotypic details are summarized in Table 2.
###end p 25
###begin title 26
Characteristics of CAD case and control study sample.
###end title 26
###begin p 27
Values denote means+/-standard deviations unless indicated otherwise. CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
###end p 27
###begin p 28
Defined as LDL-C >/=160 mg/dL or intake of lipid lowering medication.
###end p 28
###begin p 29
Defined as blood pressure >/=140/90 mmHg or ongoing antihypertensive therapy.
###end p 29
###begin p 30
Defined as history of diabetes mellitus or intake of antidiabetic medication.
###end p 30
###begin p 31
Former or current smoking habit.
###end p 31
###begin p 32
###xml 20 24 20 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Erdmann1">[11]</xref>
###xml 26 30 26 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Samani1">[12]</xref>
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Devlin1">[13]</xref>
Recent GWA analyses [11], [12] using a part of the current study sample (n = 1,021) revealed no population stratification effects within unrelated individuals form the German MI Family Study using the genomic control method [13]. Therefore, no correction for population stratification was carried out.
###end p 32
###begin title 33
SNP Selection and Genetic Analyses
###end title 33
###begin p 34
###xml 220 223 218 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Stark1">[3]</xref>
###xml 303 306 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 330 333 328 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Stark1">[3]</xref>
Genomic DNA isolation using the PureGene DNA Blood Kit (Qiagen, Hilden, Germany) and genotyping with 5' exonuclease TaqMan(R) technology (Applied Biosystems, Foster City, CA, USA) was carried out as previously described [3]. SNPs were selected from a recently published meta-analysis on serum UA levels [7] and our previous study [3].
###end p 34
###begin title 35
Statistical Analyses
###end title 35
###begin p 36
###xml 181 182 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 416 417 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1119 1120 1117 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
To determine whether the SNP genotypes of cases and controls deviated from Hardy-Weinberg equilibrium (HWE), actual and predicted genotype counts of both groups were compared by chi2-test. Differences in allele frequencies between dichotomous traits were calculated employing the same method. Prevalence odds ratios (OR) with their 95% confidence intervals (CI) were reported. Continuous parameters were compared by t test for normally distributed values or otherwise by non-parametric tests. Logistic regression was used to adjust for covariates differentially distributed in case-control cohorts. Full adjustment model for gout included gender, medication with diuretics, lipid lowering and antihypertensive therapy, high-density lipoprotein cholesterol (HDL-C), type 2 diabetes, smoking, and BMI. The corresponding model for CAD case-control sample included gender, age at inclusion, hypercholesterolemia, hypertension, type 2 diabetes, smoking, and BMI. Employing a model based on allele dosage, epistasis between SNPs was tested using a logistic regression analysis with the second SNP as a covariate. A two-sided p-value</=0.05 was considered statistically significant.
###end p 36
###begin p 37
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Purcell1">[14]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Faul1">[15]</xref>
Statistical and association analyses were performed using JMP 7.0.2 (SAS Institute Inc, Cary, NC, USA) and PLINK v1.06 [14], respectively. Power analysis was carried out using G*Power 3.0.10 employing a two-tailed exact test with minor allele frequencies (MAF) from controls [15].
###end p 37
###begin title 38
Results
###end title 38
###begin title 39
Population Characteristics
###end title 39
###begin p 40
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 779 780 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 953 960 953 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t001">Table 1</xref>
###xml 401 406 <span type="species:ncbi:9606">women</span>
In our first case-control cohort, gout cases (n = 683) were compared to control individuals (n = 1,563). Prevalence of cardiovascular risk factors and cardiovascular disease was high in both, gout cases and gout-free controls. However, we found no significant difference in number of reported MI or CAD events between gout cases (61.1% CAD/MI) and gout-free controls (58.2% CAD/MI). The proportion of women was lower in the gout group than in the control group. Gout cases were more often treated with diuretics as compared to controls. In addition and in concordance to the clinical manifestation of gout cases, the prevalence of type 2 diabetes and increased body mass index (BMI) was higher, and gout-free controls showed higher HDL-C levels, even after adjusting for gender (p<0.001). The prevalence of hypercholesterolemia was equally distributed between the two groups, whereas hypertension and smoking were slightly more prevalent in gout cases (Table 1).
###end p 40
###begin p 41
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 298 305 298 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t002">Table 2</xref>
###xml 413 420 413 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t002">Table 2</xref>
In our second, large case-control sample for CAD/MI the incidence of established cardiovascular risk factors, such as male gender, type 2 diabetes, hypercholesterolemia, hypertension and smoking, as well as increased BMI, was higher in CAD/MI cases (n = 1,473) as compared to controls (n = 1,241) (Table 2). We also found more individuals suffering from gout in our CAD/MI cases compared to CAD/MI-free controls (Table 2).
###end p 41
###begin title 42
Genetic Analyses
###end title 42
###begin p 43
###xml 49 56 49 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t003">Table 3</xref>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 236 238 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r<sup>2</sup></italic>
###xml 368 369 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 367 369 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r<sup>2</sup></italic>
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A1</italic>
###xml 439 442 439 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 458 465 458 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A3</italic>
###xml 495 498 495 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
The cohorts were genotyped for markers listed in Table 3. All SNPs fulfilled our criteria of at least 98% call rate in all sub-samples, except for rs734553 with a total call rate = 96.0%. Marker rs6855911 is in strong LD with rs734553 (r2 = 0.94) and, therefore, can to some degree be used as a surrogate. Data for rs734553 were reported for completeness. Strong LD (r2 = 0.967) exits between rs1183201 (SLC17A1) reported from Kolz et al. [7] and rs1165205 (SLC17A3) described by Dehghan et al. [6]. Therefore, a distinction between these two genes on association level is not possible.
###end p 43
###begin title 44
SNP marker used in analysis.
###end title 44
###begin p 45
###xml 3 8 <span type="species:ncbi:9606">human</span>
on human genome build 18.
###end p 45
###begin p 46
###xml 17 18 17 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
in total sample (n = 4,960).
###end p 46
###begin title 47
Association analysis of SNPs in the gout case-control sample
###end title 47
###begin p 48
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t004">Table 4</xref>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 225 228 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Stark1">[3]</xref>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 547 553 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 615 619 615 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 614 619 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p<sub>corr</sub></italic>
###xml 628 630 628 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 636 640 636 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 635 640 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p<sub>corr</sub></italic>
###xml 649 651 649 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 671 676 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 788 792 788 792 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p<sub>corr</sub></italic>
###xml 847 848 847 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 916 923 916 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t004">Table 4</xref>
###xml 1052 1058 1052 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1100 1107 1100 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRC16A</italic>
###xml 1113 1114 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1127 1128 1127 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Genotype distributions and allele frequencies in gout case-control cohort are shown in Table 4. No deviation from HWE was observed for the ten genotyped markers in gout-free controls (p>0.23). However, as previously reported [3], rs6855911 in SLC2A9 gene showed deviation from HWE in gout cases (p = 0.01). The proximate marker rs734553 also showed nominal deviation from HWE in gout cases (p = 0.05), whereas the other markers exhibited p-values>0.18. Significant association with gout was found for rs734553 and rs6855911 located in intron 7 of SLC2A9, even after correction for multiple testing (ten SNPs) with pcorr = 5.6*10-6 and pcorr = 1.1*10-6, respectively. The ABCG2 polymorphism rs2231142 remained significantly associated with gout after correction for multiple testing with pcorr = 0.013. The power to detect nominal association with p = 0.05 and OR = 1.2 for the other SNPs ranged from 32.8% to 50.4% (Table 4). Interaction between SNPs was analyzed using a model based on allele dosage. Nominal significance was observed between SNPs in SLC2A9 (rs734553 and rs6855911) and rs742132 in LRRC16A with p = 0.038 and p = 0.024, respectively.
###end p 48
###begin title 49
Association analysis results in gout case-control sample.
###end title 49
###begin p 50
###xml 60 67 60 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t003">Table 3</xref>
Numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 50
###begin p 51
Model including gender, medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI.
###end p 51
###begin p 52
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Power was calculated for the given OR using the respective MAF in controls and a two-tailed p = 0.05.
###end p 52
###begin p 53
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 224 231 224 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t005">Table 5</xref>
###xml 254 261 254 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t006">Table 6</xref>
###xml 467 474 467 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t004">Table 4</xref>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 618 625 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t005">Table 5</xref>
###xml 630 637 630 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t006">Table 6</xref>
Furthermore, we had indication for gender interaction, as separate analyses in females and males revealed association with gout for both SLC2A9 SNPs, whereas ABCG2 SNP rs2231142 only showed significant association in males (Table 5), but not in females (Table 6). Full adjustment for gender, medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI did not did not change the association results substantially (Table 4). The same model without inclusion of gender was applied in males and females separately and did not lead to a significant change in p-values (Table 5 and Table 6, respectively).
###end p 53
###begin title 54
Association analysis results in male gout case-control sample.
###end title 54
###begin p 55
###xml 60 67 60 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t003">Table 3</xref>
Numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 55
###begin p 56
Model including medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI.
###end p 56
###begin title 57
Association analysis results in female gout case-control sample.
###end title 57
###begin p 58
###xml 60 67 60 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t003">Table 3</xref>
Numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 58
###begin p 59
Model including medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI.
###end p 59
###begin title 60
Association analysis of SNPs in the CAD/MI case-control sample
###end title 60
###begin p 61
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 177 184 177 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t007">Table 7</xref>
###xml 321 328 321 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t007">Table 7</xref>
###xml 443 450 443 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t007">Table 7</xref>
Deviation from HWE was not observed for the genotyped markers in CAD/MI cases and CAD/MI-free controls (p>0.05). No association with CAD was found for any of the analyzed SNPs (Table 7). Again, adjustment for differentially distributed risk factors between CAD cases and controls did not alter the results significantly (Table 7). The power to detect nominal association with CAD was >30.3% for an assumed OR = 1.2 and >79.6% for an OR = 1.4 (Table 7).
###end p 61
###begin title 62
Association analysis results in CAD case-control sample.
###end title 62
###begin p 63
###xml 60 67 60 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007729-t003">Table 3</xref>
Numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 63
###begin p 64
Model including age at inclusion, gender, hypercholesterolemia, diabetes, hypertension, smoking, and BMI.
###end p 64
###begin p 65
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Power was calculated for the given OR using the respective MAF in controls and a two-tailed p = 0.05.
###end p 65
###begin title 66
Discussion
###end title 66
###begin p 67
###xml 362 365 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
In the present case-control association studies, we evaluated the relationship of common SNPs with gout and their potential influence on CAD. The variants are located in nine different genetic regions, four of which are known and the remaining five loci were only recently identified to be associated with serum UA levels in a large meta-analysis of GWA studies [7]. We were able to confirm significant association between gout and SNPs in two established genes, namely SLC2A9 (rs734553 and rs6855911) and ABCG2 (rs2231142). However, for markers in the other known and novel loci, no association with the clinical phenotype gout was found in our study. Moreover, our results indicate no relevant influence of the investigated polymorphisms on CAD susceptibility in our German MI Family Study.
###end p 67
###begin p 68
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 187 190 187 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Li1">[2]</xref>
###xml 191 194 191 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Anzai1">[16]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Matsuo1">[18]</xref>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Lee1">[19]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Xu1">[20]</xref>
The strongest association signal with gout was detected for intronic SNPs rs6855911 and rs734553 in the SLC2A9 gene, which is consistent with previous studies on gout and serum UA levels [2]-[6]. SLC2A9 is coding for GLUT9, a high-capacity urate transporter, which is abundantly expressed in liver and kidney tissues [16]-[18]. It is noteworthy that both SNPs located in SLC2A9 gene showed deviation from HWE in gout cases, which can in some degree support a true association [19], [20].
###end p 68
###begin p 69
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 172 175 172 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 419 422 419 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
In addition, we found a significant association between the exonic SNP rs2231142 in ABCG2 and gout, again supporting the results of a prior GWA on serum UA levels and gout [6]. This is the only marker examined that leads to a missense mutation with an amino acid exchange from glutamine to lysine at position 141 in ABCG2 transporter and therefore could have a direct and causal influence on development of the disease [6]. It is notable, however, that the effect of this variant on susceptibility to gout is only present in our male subcohort.
###end p 69
###begin p 70
###xml 207 210 207 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A1</italic>
###xml 393 400 393 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A3</italic>
###xml 442 449 442 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC17A1</italic>
###xml 549 552 549 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 745 748 745 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 1205 1208 1205 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 1522 1525 1522 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 1539 1542 1539 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 781 793 <span type="species:ncbi:9606">participants</span>
###xml 1218 1230 <span type="species:ncbi:9606">participants</span>
A recent meta-analysis documented an additional locus on chromosome 6p23-p21.3 encompassing three members of the solute carrier family 17 (SLC17A1, SLC17A3 and SLC17A4) to be associated with serum UA levels [7]. Interestingly, their top marker rs1183201 in the SLC17A1 gene did not show significant association with the qualitative trait of gout in our study. Another SNP marker, rs1165205 in SLC17A3, which is in strong LD with rs1183201 in SLC17A1 was previously found to be related to serum UA levels and also representing a risk factor for gout [6]. A possible explanation for these discrepancies may lie in the different recruitment strategies of the study populations and the distinct definition of the phenotype "gout". While Kolz et al. [7] in their meta-analysis examined participants of European ancestry from 14 different study cohorts with widely varying initial inclusion criteria - potentially concealing a substructure which could lead to false positive results - our ascertainment approach was to recruit individuals with a strong familial history of CAD from all over Germany with a concomitant accumulation of cardiometabolic risk factors, such as gout. On the other hand, Deghan et al. [6] included participants from three large population-based studies (Framingham cohort, Rotterdam cohort and the Atherosclerosis Risk in Communities (ARIC) study) with different definitions of gout in each of the study cohorts. It is important to notice, that the allele frequencies between Deghan et al. (rs1165205) [6], Kolz et al. [7] and our present study (both rs1183201) did not differ substantially (47%, 48% and 48%, respectively).
###end p 70
###begin p 71
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Annemans1">[21]</xref>
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Mandell1">[22]</xref>
###xml 868 872 868 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Mandell1">[22]</xref>
###xml 1103 1111 1103 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC22A12</italic>
###xml 1154 1158 1154 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Enomoto1">[23]</xref>
###xml 1166 1174 1166 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC22A12</italic>
###xml 1222 1225 1222 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 1379 1382 1379 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dehghan1">[6]</xref>
###xml 1609 1614 1609 1614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 1619 1625 1619 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1803 1806 1803 1806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 1995 1998 1995 1998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
###xml 770 776 <span type="species:ncbi:9606">people</span>
The same might hold true for the other SNPs that were genotyped in our present study but showed no significant association with the phenotype gout. However, one has to emphasize that in our study, we explicitly investigated the role of SNP markers with clinically manifest gout or gouty arthritis, for which elevated serum UA levels are an important but not a mandatory risk factor [21], [22]. Therefore, differences in the pathophysiological pathways of the development of elevated serum UA levels and the ignition of the inflammatory process of gout or gouty arthritis may account for the distinct findings of our study. This is also reflected by the clinical observations that many patients with high serum UA levels never experience an attack of gout, whereas other people in the absence of hyperuricemia suffer from severe and recurrent flares of gouty arthritis [22]. One can speculate that other pathophysiological mechanisms might be involved, or a complex interplay of genes and their variants lead to the manifestation of the disease. For example, the well-known URAT1 transporter, encoded by SLC22A12 gene, is involved in renal urate exchange [23], and a SLC22A12 polymorphism is also linked to serum UA levels [7]. Therefore, this gene is a strong candidate for gout, but does not show significant association with the clinical phenotype in this and a previous study [6]. Another possible explanation is the small effect size of some polymorphisms on serum UA levels that could directly impact susceptibility to gout. Our present study showed a high degree of association between gout and SNPs in ABCG2 and SLC2A9, those polymorphisms that were reported to have highest effects on serum UA levels found in the previous meta-analysis (explaining 0.57% and 3.53% of variability, respectively) [7] and that showed ORs for gout between 1.37 and 1.52 in our study. All other SNPs were significant on a genome-wide level, but explained less the variability of serum UA levels (below 0.2%) [7]. Therefore, either power was not sufficient for detection of association between these SNPs and gout in the present study, or their relevance on the clinical phenotype gout is not evident.
###end p 71
###begin p 72
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRRC16A</italic>
Additionally, we found only weak epistatic interaction between SNPs in SLC2A9 and LRRC16A on gout, making a relevant additive effect of SNPs influencing serum UA levels on the qualitative trait unlikely. Potential confounders, such as different medications and prevalence of type 2 diabetes, smoking or BMI, did not influence the association results significantly. Taken together, it is obvious that SNPs with highest influence on serum UA levels could be directly linked to susceptibility to gout, whereas the relevance of less contributing polymorphisms is still arguable.
###end p 72
###begin p 73
More complex functional studies are warranted in the future to elucidate the pathways with which the newly identified genes impact serum UA levels and development of gout.
###end p 73
###begin p 74
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Abbott1">[24]</xref>
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Feig1">[28]</xref>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Erdmann1">[11]</xref>
###xml 911 915 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Samani1">[12]</xref>
###xml 917 921 917 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Wellcome1">[29]</xref>
###xml 922 926 922 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Tregouet1">[32]</xref>
Furthermore, the presence of hyperuricemia and gout has often been discussed to be a cardiovascular risk factor [24]-[28]. We thus examined the SNPs being associated with elevated UA serum levels in our second case-control study consisting of CAD cases and controls from the general population. Here, we did not detect a direct genetic relationship between the tested SNPs and CAD. One possible explanation may be limited power: polymorphisms with a small effect on disease susceptibility require very large study samples to be detected. Therefore, we cannot rule out a causal link between the SNPs influencing serum UA levels and CAD. On the other hand, CAD is possibly a more heterogeneous disorder than gout, even on genetic level. For example, no genes known to influence serum UA levels were identified by recent GWA studies on CAD, but genetic loci involved in several different pathways were found [11], [12], [29]-[32].
###end p 74
###begin p 75
###xml 222 225 222 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Kolz1">[7]</xref>
###xml 1040 1043 1040 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007729-Dring1">[4]</xref>
###xml 1148 1153 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
###xml 446 453 <span type="species:ncbi:9606">patient</span>
###xml 805 817 <span type="species:ncbi:9606">participants</span>
###xml 1122 1130 <span type="species:ncbi:9606">patients</span>
###xml 1352 1360 <span type="species:ncbi:9606">patients</span>
###xml 1502 1510 <span type="species:ncbi:9606">patients</span>
There are limitations in our study design that have to be considered. First, we do not have measurement of serum UA levels in our cohort. Hence, we can not directly replicate the findings of Kolz et al. on serum UA levels [7]. However, we did not aim in replication of serum UA level association but in expansion of these results to clinical manifestation of the phenotypes gout and CAD. Second, all phenotypes were assessed retrospectively from patient documentations and medical history readings. When gout was diagnosed by a physician according to ICD-9 code 274, the phenotype gout was considered as confirmed. In case of self-reported gout, additional intake of uricostatic or uricosuric medication was required to affirm the diagnosis of gout. We have follow-up data from more than 80% of our study participants and, therefore, validation of clinicial phenotypes is available. Third, the power to analyze gender effects in our study is limited. As previously described, association of serum UA levels depends to some degree on gender [4]. Our findings on gender-specific association between male but not female gout patients and rs2231142 in ABCG2 gene are likely to be true positive results but some other gender effects may have been overlooked. Forth, assuming that gout is a risk factor for CAD, we expected to observe significantly more CAD patients in the gout sample than in gout-free controls. However, based on our initial ascertainment strategy where we retrospectively identified gout patients and gout-free controls from a MI/CAD study cohort, we did not find a significant coincidence of CAD and gout. On the other hand, in our CAD case-control sample we found that the clinical phenotype of gout seems to be associated with CAD.
###end p 75
###begin p 76
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG2</italic>
In conclusion, we performed a comprehensive analysis on association with susceptibility to gout and CAD of recently published polymorphisms known to be linked with serum UA levels. Markers in SLC2A9 and ABCG2 genes are strongly associated with clinical manifestation of gout in the German MI Family Study. With the knowledge of a comprehensive number of genetic polymorphisms contributing to gout, genetic testing as a supportive diagnostic tool would be conceivable.
###end p 76
###begin p 77
###xml 45 57 <span type="species:ncbi:9606">participants</span>
We appreciate the invaluable contribution of participants of the German MI Family Study. We gratefully acknowledge the excellent technical assistance of Josef Simon and Michaela Vostner.
###end p 77
###begin title 78
References
###end title 78
###begin article-title 79
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
###end article-title 79
###begin article-title 80
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts.
###end article-title 80
###begin article-title 81
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study.
###end article-title 81
###begin article-title 82
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.
###end article-title 82
###begin article-title 83
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.
###end article-title 83
###begin article-title 84
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.
###end article-title 84
###begin article-title 85
Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.
###end article-title 85
###begin article-title 86
Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.
###end article-title 86
###begin article-title 87
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey.
###end article-title 87
###begin article-title 88
###xml 91 94 <span type="species:ncbi:9606">men</span>
Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.
###end article-title 88
###begin article-title 89
New susceptibility locus for coronary artery disease on chromosome 3q22.3.
###end article-title 89
###begin article-title 90
Genomewide association analysis of coronary artery disease.
###end article-title 90
###begin article-title 91
Genomic control for association studies.
###end article-title 91
###begin article-title 92
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 92
###begin article-title 93
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.
###end article-title 93
###begin article-title 94
###xml 105 111 <span type="species:ncbi:9606">humans</span>
Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
###end article-title 94
###begin article-title 95
###xml 47 53 <span type="species:ncbi:9606">humans</span>
SLC2A9 is a high-capacity urate transporter in humans.
###end article-title 95
###begin article-title 96
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia.
###end article-title 96
###begin article-title 97
Searching for disease-susceptibility loci by testing for Hardy-Weinberg disequilibrium in a gene bank of affected individuals.
###end article-title 97
###begin article-title 98
Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error?
###end article-title 98
###begin article-title 99
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
###end article-title 99
###begin article-title 100
Clinical manifestations of hyperuricemia and gout.
###end article-title 100
###begin article-title 101
Molecular identification of a renal urate anion exchanger that regulates blood urate levels.
###end article-title 101
###begin article-title 102
Gout and coronary heart disease: the Framingham Study.
###end article-title 102
###begin article-title 103
Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?
###end article-title 103
###begin article-title 104
Independent impact of gout on mortality and risk for coronary heart disease.
###end article-title 104
###begin article-title 105
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.
###end article-title 105
###begin article-title 106
Uric acid and cardiovascular risk.
###end article-title 106
###begin article-title 107
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 107
###begin article-title 108
A common variant on chromosome 9p21 affects the risk of myocardial infarction.
###end article-title 108
###begin article-title 109
A common allele on chromosome 9 associated with coronary heart disease.
###end article-title 109
###begin article-title 110
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
###end article-title 110
###begin p 111
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 111
###begin p 112
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by grants from the National Genome Network (NGFNplus Atherogenomics, 01GS0831), Deutsche Forschungsgemeinschaft (He1921/9-1), the Vaillant-Stiftung (C.H., H.S.), the Deutsche Stiftung fuer Herzforschung, and the EU sponsored project Cardiogenics (LSH-2006-037593). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 112

